Tweedy Browne Co. Ionis Pharmaceuticals Inc Transaction History

Tweedy, Browne CO LLC

$1.42 Billion
Q4 2024

A detailed history of Tweedy Browne Co. (Tweedy, Browne CO LLC) transactions in Ionis Pharmaceuticals Inc stock. As of the latest transaction made, Tweedy, Browne CO LLC holds 3,248,863 shares of IONS stock, worth $107 Million. This represents 7.97% of its overall portfolio holdings.

Number of Shares

3,248,863

Previous 3,454,676 5.96%

Holding current value

$107 Million

Previous $138 Million 17.93%

% of portfolio

7.97%

Previous 6.83%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2024 Feb 12, 2025	SELL	$33.73 - $40.36 $6.94 Million - $8.31 Million	-205,813 Reduced 5.96%	3,248,863 $114 Million
Q4 2023 Feb 13, 2024	SELL	$43.39 - $51.63 $2.41 Million - $2.87 Million	-55,497 Reduced 1.58%	3,454,676 $175 Million
Q3 2023 Nov 13, 2023	SELL	$38.5 - $47.13 $1.18 Million - $1.45 Million	-30,685 Reduced 0.87%	3,510,173 $159 Million
Q2 2023 Aug 14, 2023	SELL	$34.73 - $43.33 $6,529 - $8,146	-188 Reduced 0.01%	3,540,858 $145 Million
Q1 2023 May 15, 2023	SELL	$33.58 - $41.2 $3,022 - $3,708	-90 Reduced -0.0%	3,541,046 $127 Million
Q4 2022 Feb 09, 2023	BUY	$37.12 - $46.52 $30.4 Million - $38.1 Million	818,148 Added 30.05%	3,541,136 $134 Million
Q3 2022 Nov 15, 2022	SELL	$36.54 - $48.66 $138,486 - $184,421	-3,790 Reduced 0.14%	2,722,988 $120 Million
Q2 2022 Aug 12, 2022	SELL	$31.71 - $43.0 $6.29 Million - $8.53 Million	-198,324 Reduced 6.78%	2,726,778 $101 Million
Q1 2022 May 13, 2022	BUY	$29.88 - $37.04 $87.4 Million - $108 Million	2,925,102 New	2,925,102 $108 Million

Others Institutions Holding IONS

# of Institutions

412

Shares Held

140M

Call Options Held

829K

Put Options Held

789K

View Full List

About IONIS PHARMACEUTICALS INC

Ticker IONS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,940,992
Market Cap $4.67B
Description
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...

More about IONS

Track Tweedy Browne Co.'s Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tweedy, Browne CO LLC, based on Form 13F filings with the SEC.

News

Stay updated on Tweedy, Browne CO LLC and Tweedy Browne Co. with notifications on news.

Account